← All trials
NCT04275232
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2020
- Primary completion
- May 31, 2022
- Completion date
- May 31, 2022
- First posted
- Feb 19, 2020
- Last posted
- Feb 19, 2020
- Enrollment
- 1
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Memorial University of NewfoundlandLead sponsor
- Memorial University of NewfoundlandSponsor investigator
- Memorial University of NewfoundlandOverall official - principal investigator
- Canadian Blood ServicesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.